For most people newly diagnosed with chronic hepatitis C who have not yet developed cirrhosis, eight weeks of treatment is genuinely enough to cure the infection. That is not a qualified maybe or a hopeful projection — it is the conclusion supported by large clinical trials and an FDA-approved regimen. MAVYRET (glecaprevir/pibrentasvir), the only pangenotypic direct-acting antiviral approved for an eight-week course, has cured 943 of 965 treatment-naïve patients without cirrhosis across all major genotypes in integrated analyses, a cure rate of 97.7 percent. In June 2025, the FDA expanded MAVYRET’s indication further, making it the first and only direct-acting antiviral therapy approved for acute hepatitis C — again at just eight weeks, with a 96 percent cure rate and zero virologic failures in the pivotal trial.
This matters beyond hepatology. For readers of this site focused on brain health and dementia care, hepatitis C is not a distant concern. Chronic HCV infection has been linked in epidemiological research to increased risk of cognitive impairment and cerebrovascular disease, and the inflammatory burden of untreated infection can compound other neurological vulnerabilities. A shorter, well-tolerated treatment course means fewer barriers to getting the virus out of someone’s body — particularly for older adults, caregivers managing multiple health conditions, or people already navigating cognitive decline. This article walks through who actually qualifies for the eight-week regimen, what the cure rate data look like compared to longer courses, how cost factors into the equation, what the research says about even shorter treatment durations, and where the global effort to eliminate hepatitis C stands heading into 2026.
Table of Contents
- Who Qualifies for an 8-Week Hepatitis C Treatment Duration — and Who Needs Longer?
- What Does a 97.7 Percent Cure Rate Actually Mean in Practice?
- How the Eight-Week Course Was Validated for Acute Hepatitis C
- MAVYRET Versus Epclusa — Comparing Cost, Duration, and Coverage
- Why Shorter Than Eight Weeks Still Falls Short
- Hepatitis C and Brain Health — Why This Matters for Dementia Caregivers
- The Global Push to Eliminate Hepatitis C by 2030
- Conclusion
- Frequently Asked Questions
Who Qualifies for an 8-Week Hepatitis C Treatment Duration — and Who Needs Longer?
The eligibility criteria for eight-week MAVYRET are specific and worth understanding clearly, because not every patient with hepatitis C can take the shorter course. The straightforward candidates are treatment-naïve adults and children aged three and older who have chronic HCV of any genotype (1 through 6) and who do not have cirrhosis. If you have never been treated for hepatitis C before and your liver has not progressed to cirrhosis, eight weeks is the standard recommendation under current AASLD-IDSA guidelines. The picture changes with liver damage or prior treatment failure. Patients with compensated cirrhosis — classified as Child-Pugh A, meaning the liver is scarred but still functioning adequately — require twelve weeks of MAVYRET rather than eight.
Those who have previously been treated with an NS5A inhibitor or an NS3/4A protease inhibitor need twelve or even sixteen weeks, depending on their specific treatment history and genotype. And some patients are excluded from MAVYRET entirely: anyone with decompensated cirrhosis (Child-Pugh B or C), liver or kidney transplant recipients, or individuals with a history of hepatic decompensation should not take this drug at all. Consider a practical example. A 68-year-old woman diagnosed with genotype 1 hepatitis C during routine blood work, with no prior treatment and a FIB-4 score suggesting minimal fibrosis, is an ideal candidate for the eight-week course. Her 72-year-old husband, diagnosed at the same time but found to have compensated cirrhosis on imaging, would need twelve weeks of the same medication. Same household, same virus, different treatment durations — and both with excellent odds of cure.
What Does a 97.7 Percent Cure Rate Actually Mean in Practice?
When hepatologists talk about curing hepatitis C, they use a specific benchmark: SVR12, or sustained virologic response at twelve weeks after completing treatment. This means the virus is undetectable in the blood — below roughly 25 international units per milliliter — three months after the last pill. Achieving SVR12 is considered a virologic cure, and long-term follow-up studies have shown that relapse rates after SVR12 hover between zero and one percent over four to five years. For practical purposes, once you hit SVR12, the virus is gone. The integrated analysis of MAVYRET across genotypes 1 through 6 in non-cirrhotic patients showed 943 of 965 patients (97.7 percent) achieved SVR12 with the eight-week course. For comparison, 1,060 of 1,076 patients (98.5 percent) achieved the same outcome with twelve weeks.
That 0.8 percentage point difference is real but small, and in clinical decision-making it has not been considered significant enough to justify routinely extending treatment in patients who meet the eight-week criteria. The twelve-week course exists for populations where the virus is harder to eradicate — those with cirrhosis, certain treatment histories, or genotype 3 infection, where SVR rates can dip to 85 to 95 percent even with longer courses. However, a caveat matters here: these cure rates come from clinical trials with structured follow-up and adherence support. In real-world settings, missed doses, treatment interruptions, and loss to follow-up can reduce effectiveness. For older adults managing multiple medications — common in the dementia care population — pill organizers and caregiver involvement in medication management are not trivial considerations. They are part of what makes the cure rate translate from a trial statistic to an actual outcome.
How the Eight-Week Course Was Validated for Acute Hepatitis C
The June 2025 FDA approval for acute hepatitis C was a meaningful expansion because acute infection — meaning within the first six months of contracting the virus — had previously been a gap in approved treatment options. Many clinicians were already treating acute HCV off-label with direct-acting antivirals, but having a formally approved indication changes insurance coverage, prescribing confidence, and guideline recommendations. The approval was based on the M20-350 Phase 3 trial, which enrolled 286 treatment-naïve adults with acute HCV across 70 sites globally. Patients took MAVYRET once daily for eight weeks and were then followed for twelve weeks post-treatment.
The cure rate was 96 percent, with no virologic failures — meaning the small number of patients who did not achieve SVR12 were lost to follow-up or discontinued for other reasons, not because the drug failed to suppress the virus. The most common side effects were mild to moderate: fatigue, headache, and diarrhea, none of which are unusual for this drug class. This is relevant for the brain health audience because acute hepatitis C infections are not limited to younger populations. Outbreaks in long-term care facilities have been documented, often linked to lapses in infection control during blood glucose monitoring or injection practices. When an acute infection is identified in a care setting, having an approved, short-duration treatment with a known safety profile simplifies the clinical response considerably.
MAVYRET Versus Epclusa — Comparing Cost, Duration, and Coverage
The two dominant pangenotypic hepatitis C treatments on the market are MAVYRET and Epclusa (sofosbuvir/velpatasvir), and they differ meaningfully in both duration and cost. Epclusa’s standard course is twelve weeks for all genotypes — there is no approved eight-week Epclusa regimen. MAVYRET’s eight-week option for eligible patients is a genuine distinguishing advantage, particularly when cost and adherence burden are factored in. On pricing, the difference is stark. An eight-week course of MAVYRET runs approximately $26,400 at wholesale, based on roughly $13,200 per month. Extending to twelve weeks brings the cost to about $39,600.
Epclusa’s twelve-week course lists at approximately $78,078, though generic versions of sofosbuvir/velpatasvir have become available with coupon prices starting around $7,683 to $7,766 — a fraction of the brand-name cost. Both manufacturers offer copay assistance programs that can reduce out-of-pocket costs to as little as five dollars per month for commercially insured patients. AbbVie’s myAbbVie Assist program provides MAVYRET free to qualifying uninsured or underinsured patients. The practical tradeoff is this: MAVYRET’s eight-week course reduces treatment cost by roughly 33 percent compared to twelve weeks of the same drug, and the shorter duration means fewer refills, fewer chances for adherence gaps, and an earlier finish line. For patients on fixed incomes or those whose caregivers are managing complex medication schedules, those four fewer weeks are not abstract — they represent real logistical relief. But if a patient qualifies for generic Epclusa at the lower price point, the twelve-week course may actually cost less out of pocket than brand-name MAVYRET, even at eight weeks. The right choice depends on insurance formulary, copay structure, and individual clinical factors.
Why Shorter Than Eight Weeks Still Falls Short
Researchers have naturally asked whether treatment could be compressed further — to six weeks or even four. The results so far suggest that eight weeks is close to the floor for reliable cure rates with current drugs. A small study of MAVYRET given for six weeks showed promising results in patients with recently acquired hepatitis C, curing almost all participants. But the TARGET3D pilot study, which tested a four-week course in 23 participants, produced only a 78 percent cure rate overall. That is substantially below the 90 percent threshold that guidelines and clinicians consider acceptable, and it means roughly one in five patients would need retreatment — an outcome that erases any savings in time or cost.
The EASE study, published in The Lancet in 2025, took a different approach by testing an alternative drug combination — ravidasvir plus sofosbuvir — for eight weeks and demonstrated non-inferiority to twelve-week regimens in non-cirrhotic patients. This regimen reduced cost by 40 percent and was approved by Malaysia’s National Pharmaceutical Regulatory Agency. It represents a path forward for low- and middle-income countries where MAVYRET pricing remains a barrier, but it also reinforces the eight-week mark as the practical minimum rather than a waypoint toward something shorter. The limitation to flag for patients and caregivers: if someone does not complete the full eight-week course — if they stop at six weeks because they feel fine, or because refills lapse — the odds of relapse increase. Feeling well during treatment is expected, since hepatitis C often produces few obvious symptoms, but it is not the same as being cured. The SVR12 check at twelve weeks post-treatment is the definitive confirmation, and it should not be skipped.
Hepatitis C and Brain Health — Why This Matters for Dementia Caregivers
Hepatitis C is not commonly discussed in the context of neurological health, but there is a meaningful intersection. Chronic HCV infection drives systemic inflammation and has been associated in observational studies with increased rates of cerebrovascular events and cognitive impairment. Some research has suggested that successful HCV treatment may reduce the risk of stroke and slow certain trajectories of cognitive decline, though these findings are still being refined. For individuals already living with mild cognitive impairment or early dementia, the added inflammatory burden of an untreated hepatitis C infection is an avoidable compounding factor.
From a caregiving perspective, the eight-week treatment duration is particularly valuable. Managing a twelve- or sixteen-week medication regimen for someone with memory difficulties is harder than managing an eight-week one. The pill count is lower, the monitoring window is shorter, and the overall cognitive and logistical load on both patient and caregiver is reduced. If a family member or care facility resident is found to have hepatitis C and meets the criteria for the short course, there is a strong practical argument for pursuing treatment promptly rather than deferring it.
The Global Push to Eliminate Hepatitis C by 2030
The World Health Organization estimates that 50 million people worldwide are living with hepatitis C, with roughly 6,000 new infections occurring every day. WHO’s 2030 elimination targets call for a 90 percent reduction in new infections and a 65 percent reduction in hepatitis-related mortality. As of 2025, only five countries — Australia, Egypt, Georgia, Japan, and Rwanda — have met the interim 2025 treatment coverage target of 50 percent. Only Egypt has reached the 2030 target of 80 percent coverage. Eight-week regimens are central to the elimination strategy because they reduce both cost and the operational burden of treatment delivery.
In resource-limited settings, every additional week of treatment means more clinic visits, more supply chain complexity, and more opportunities for patients to disengage. The approval of shorter regimens like MAVYRET and the EASE study’s ravidasvir-sofosbuvir combination are not just clinical milestones — they are logistical ones. Whether elimination targets are met by 2030 will depend less on whether effective drugs exist and more on whether health systems can deliver them at scale. The drugs are ready. The infrastructure, in most of the world, is not.
Conclusion
Eight weeks of MAVYRET can cure hepatitis C in treatment-naïve patients without cirrhosis, across all major genotypes, with a cure rate above 97 percent. The June 2025 FDA expansion to acute hepatitis C reinforced that this duration is sufficient and safe when patients are properly selected. For those with cirrhosis, prior treatment experience, or certain complicating factors, longer courses of twelve or sixteen weeks remain necessary — and for some patients, MAVYRET is contraindicated entirely. The clinical distinction between who qualifies for the short course and who does not is sharp and must be respected.
For readers focused on brain health and dementia care, the practical takeaway is this: hepatitis C is treatable, the treatment is short, and there are financial assistance programs that can reduce cost to near zero. If someone in your care has hepatitis C or is at risk — particularly in congregate living settings — screening and treatment are straightforward interventions that remove a source of systemic inflammation and potential neurological harm. Talk to a hepatologist or infectious disease specialist, confirm eligibility for the eight-week regimen, and follow through to the SVR12 confirmation. That is the whole path from diagnosis to cure.
Frequently Asked Questions
What does SVR12 mean, and is it really a cure?
SVR12 stands for sustained virologic response at 12 weeks post-treatment — meaning the hepatitis C virus is undetectable in the blood three months after finishing medication. Long-term studies show relapse rates of zero to one percent over four to five years after achieving SVR12, so it is considered a definitive virologic cure by hepatology guidelines.
Can children receive the eight-week MAVYRET treatment?
Yes. MAVYRET is approved for patients aged three years and older. Pediatric dosing is weight-based, and the eight-week duration applies to treatment-naïve children without cirrhosis, the same criteria as for adults.
What happens if I miss doses during the eight-week course?
Missed doses can reduce the drug’s effectiveness and increase the risk of treatment failure or viral resistance. If a dose is missed, patients should take it as soon as possible unless it is nearly time for the next dose. Caregivers managing medication for someone with cognitive difficulties should use pill organizers and reminders to minimize gaps.
Is the eight-week regimen safe for older adults with multiple health conditions?
MAVYRET is generally well tolerated, with the most common side effects being fatigue, headache, and diarrhea. However, it has known drug interactions — particularly with certain statins, blood thinners, and seizure medications — that require review. A hepatologist should evaluate all current medications before starting treatment, especially in older adults on complex regimens.
Why can’t patients with cirrhosis take the shorter course?
Cirrhosis alters how the liver processes medication and how effectively the virus can be cleared. Patients with compensated cirrhosis (Child-Pugh A) need twelve weeks to achieve comparable cure rates. Those with decompensated cirrhosis (Child-Pugh B or C) cannot take MAVYRET at all due to safety concerns related to severely impaired liver function.
Does curing hepatitis C reverse liver damage?
Curing the virus stops ongoing liver inflammation and can allow some degree of fibrosis regression over time, particularly in patients without advanced scarring. However, cirrhosis is generally not fully reversible, and patients with significant liver damage still need ongoing monitoring for complications including liver cancer, even after achieving SVR12.
